Market Summary
USD137.22+2.33
Delayed1.73%
JAZZ Stock Price
JAZZ RSI Chart
JAZZ Valuation
JAZZ Price/Sales (Trailing)
JAZZ Profitability
JAZZ Fundamentals
JAZZ Revenue
JAZZ Earnings
Price Action
52 Week Range
125.36169.98
(Low)(High)
Last 7 days
-3.5%
Last 30 days
-10.9%
Last 90 days
-11.8%
Trailing 12 Months
-12.8%
JAZZ Financial Health
JAZZ Investor Care
Peers (Alternatives to Jazz Pharmaceuticals)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
JNJ | 404.8B | 94.9B | -5.16% | -10.64% | 22.56 | 4.26 | 1.25% | -14.07% |
LLY | 296.8B | 28.5B | -5.67% | 20.74% | 47.53 | 10.4 | 0.79% | 11.88% |
MRK | 272.8B | 59.3B | -1.75% | 40.02% | 17.88 | 4.63 | 21.72% | 11.27% |
PFE | 226.4B | 100.3B | -8.43% | -20.95% | 7.22 | 2.26 | 23.43% | 42.74% |
BMY | 142.7B | 46.2B | -7.78% | -1.12% | 22.55 | 3.09 | -0.49% | -9.54% |
| MID-CAP | ||||||||
PRGO | 4.8B | 4.5B | -0.20% | -5.41% | -34.17 | 1.08 | 7.56% | -104.06% |
RETA | 3.3B | 2.2M | 105.10% | 171.03% | -10.52 | 1.5K | -80.71% | -4.88% |
| SMALL-CAP | ||||||||
SUPN | 1.9B | 667.2M | -9.96% | 17.66% | 31.57 | 2.87 | 15.09% | 13.64% |
TLRY | 1.6B | 602.5M | -17.77% | -52.80% | -2.74 | 2.63 | 18.18% | -18.59% |
CGC | 991.7M | 478.9M | -11.35% | -65.42% | -0.32 | 2.07 | -31.50% | -634.70% |
INVA | 792.9M | 285.2M | -7.22% | -37.95% | 3.6 | 2.78 | -27.21% | -40.28% |
CRON | 768.8M | 114.5M | -15.28% | -37.42% | -4.56 | 6.72 | 27.90% | 57.40% |
ACRS | 541.5M | 29.8M | -40.95% | -47.43% | -6.23 | 18.2 | 340.05% | 4.35% |
OCUL | 400.7M | 51.5M | -2.49% | -0.39% | -5.64 | 7.78 | 18.32% | -984.05% |
ENDP | 94.1M | 2.3B | -43.99% | -88.43% | -0.03 | 0.04 | -22.53% | -376.66% |
Financials for Jazz Pharmaceuticals
| Income Statement (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Revenue | 2.1% | 3,659 | 3,584 | 3,481 | 3,300 | 3,094 |
| S&GA Expenses | -1.1% | 1,417 | 1,432 | 1,437 | 1,500 | 1,452 |
| EBITDA | -623.5% | -342 | -47.34 | -54.66 | -122 | - |
| EBITDA Margin | -608.6% | -0.09* | -0.01* | -0.02* | -0.04* | - |
| Earnings Before Taxes | -380.3% | -372 | -77.62 | -85.12 | -242 | -112 |
| EBT Margin | -370.4% | -0.10* | -0.02* | -0.02* | -0.07* | - |
| Interest Expenses | - | 138 | - | - | - | - |
| Net Income | -1099.0% | -224 | -18.69 | -51.87 | -449 | -329 |
| Net Income Margin | -1074.3% | -0.06* | -0.01* | -0.01* | -0.14* | - |
| Free Cahsflow | 15.3% | 1,243 | 1,078 | 921 | 665 | - |
| Balance Sheet | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Assets | 4.3% | 10,835 | 10,385 | 11,200 | 11,769 | 12,299 |
| Current Assets | 1.3% | 2,606 | 2,572 | 2,591 | 2,501 | 2,611 |
| Cash Equivalents | 5.0% | 881 | 839 | 711 | 491 | 591 |
| Inventory | -1.9% | 714 | 728 | 862 | 985 | 1,073 |
| Goodwill | 6.3% | 1,693 | 1,593 | 1,688 | 1,782 | 1,828 |
| Current Liabilities | 14.8% | 933 | 813 | 705 | 737 | 809 |
| Long Term Debt | -4.9% | 5,727 | 6,021 | 6,024 | 6,050 | - |
| LT Debt, Current | 0% | 31.00 | 31.00 | 31.00 | 31.00 | 31.00 |
| LT Debt, Non Current | 0.0% | 5,693 | 5,696 | 5,990 | 5,993 | 6,019 |
| Shareholder's Equity | 12.4% | 3,086 | 2,745 | 3,201 | 3,608 | 3,965 |
| Retained Earnings | -24.7% | 734 | 974 | 994 | 959 | 830 |
| Additional Paid-In Capital | 2.6% | 3,477 | 3,388 | 3,312 | 3,239 | 3,535 |
| Shares Outstanding | 0.6% | 63.00 | 62.00 | 62.00 | 62.00 | - |
| Cashflow (Last 12 Months) | (In Millions) | |||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
| Cashflow From Operations | 14.8% | 1,272 | 1,108 | 964 | 702 | 779 |
| Share Based Compensation | 4.0% | 222 | 214 | 210 | 205 | 189 |
| Cashflow From Investing | -238.2% | -446 | -131 | -163 | -5,986 | -5,212 |
| Cashflow From Financing | 33.5% | -529 | -795 | -971 | 3,681 | 3,971 |
| Buy Backs | -25.0% | 0.00 | 0.00 | 0.00 | 0.00 | - |
Risks for JAZZ
What is the probability of a big loss on JAZZ?
69.6%
Probability that Jazz Pharmaceuticals stock will be more than 20% underwater in next one year
49.6%
Probability that Jazz Pharmaceuticals stock will be more than 30% underwater in next one year.
0%
Probability that Jazz Pharmaceuticals stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does JAZZ drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Jazz Pharmaceuticals was unfortunately bought at previous high price.
Drawdowns
Returns for JAZZ
Cumulative Returns on JAZZ
8.6%
10-Year Cumulative Returns
1.6%
7-Year Cumulative Returns
-2.6%
5-Year Cumulative Returns
6.6%
3-Year Cumulative Returns
What are the long-term rolling returns for JAZZ?
FIve years rolling returns for Jazz Pharmaceuticals.
Annualized Returns
Which funds bought or sold JAZZ recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | reduced | -32.2 | -20,389,000 | 87,136,000 | 0.10% |
2023-03-10 | BAILLIE GIFFORD & CO | unchanged | - | 4,764 | 26,764 | -% |
2023-03-06 | Rockefeller Capital Management L.P. | added | 4.74 | 1,244,000 | 6,182,000 | 0.03% |
2023-03-02 | OLIVER LAGORE VANVALIN INVESTMENT GROUP | reduced | -7.69 | -88.00 | 1,912 | -% |
2023-02-28 | Voya Investment Management LLC | reduced | -25.54 | -973,130 | 7,870,870 | 0.01% |
2023-02-24 | SRS Capital Advisors, Inc. | unchanged | - | 2,152 | 11,152 | -% |
2023-02-22 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 0.51 | 4,173,000 | 24,896,000 | 0.26% |
2023-02-21 | NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO | reduced | -3.24 | 52,530 | 385,530 | -% |
2023-02-21 | MACQUARIE GROUP LTD | added | 11.01 | 1,191,840 | 4,839,840 | 0.01% |
2023-02-17 | TRUIST FINANCIAL CORP | added | 6.62 | 1,244,580 | 5,776,580 | 0.01% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Jazz Pharmaceuticals News
Schedule 13G FIlings of Jazz Pharmaceuticals
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 9.61% | 6,050,625 | SC 13G/A | |
| Jan 26, 2023 | blackrock inc. | 10.6% | 6,652,382 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 10.6% | 6,652,382 | SC 13G | |
| Jan 05, 2023 | jpmorgan chase & co | 4.6% | 2,924,604 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A | |
| Jan 28, 2022 | blackrock inc. | 10.5% | 6,450,368 | SC 13G/A | |
| Jan 24, 2022 | jpmorgan chase & co | 5.2% | 3,248,156 | SC 13G | |
| Feb 11, 2021 | renaissance technologies llc | 5.56% | 3,099,050 | SC 13G/A | |
| Feb 10, 2021 | vanguard group inc | 8.76% | 4,877,893 | SC 13G/A | |
| Feb 08, 2021 | fmr llc | - | 0 | SC 13G |
JAZZ Fair Value
Jazz Pharmaceuticals fair value in different scenarios
The table shows the Fair Value estimates for Jazz Pharmaceuticals for various scenarios. Disclaimer: These are just estimations from a model. None of the models are good at predicting the future. Please dont buy or sell stocks based on these outputs.
| Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
|---|---|---|---|---|---|
| Very Low Inflation | - - | - - | - - | - - | - - |
| Current Inflation | 89.88 -34.50% | 110.26 -19.65% | 153.07 11.55% | 198.25 44.48% | 231.66 68.82% |
| Very High Inflation | - - | - - | - - | - - | - - |
Historical Jazz Pharmaceuticals Fair Value Estimates
Very Pessimistic Case
Pessimistic Case
Fair Value
Optimistic Case
Very Optimistic Case
Closing Stock Price
Recent SEC filings of Jazz Pharmaceuticals
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Mar 10, 2023 | 4 | Insider Trading | |
| Mar 09, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading | |
| Mar 07, 2023 | 4 | Insider Trading |
Latest Insider Trading transactions for JAZZ
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-08 | Sablich Kim | sold | -421,043 | 139 | -3,013 | evp, gm of u.s., commercial ma |
2023-03-07 | O'Keefe Kenneth W | acquired | 367,920 | 81.76 | 4,500 | - |
2023-03-07 | Larkin Finbar | sold | -292,081 | 140 | -2,075 | svp, technical operations |
2023-03-07 | O'Keefe Kenneth W | sold | -372,268 | 138 | -2,690 | - |
2023-03-06 | Larkin Finbar | acquired | 100,176 | 58.72 | 1,706 | svp, technical operations |
2023-03-06 | Larkin Finbar | sold | -245,526 | 143 | -1,706 | svp, technical operations |
2023-03-05 | Patil Neena M | sold (taxes) | -274,566 | 142 | -1,923 | evp & chief legal officer |
2023-03-05 | Carr Patricia | sold | -161,594 | 140 | -1,148 | svp, chief accounting officer |
2023-03-05 | Iannone Robert | sold (taxes) | -324,682 | 142 | -2,274 | evp, global head of research a |
2023-03-05 | Swisher Daniel N JR | sold (taxes) | -774,724 | 142 | -5,426 | president and coo |
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.
JAZZ Income Statement
2022-12-31CONSOLIDATED STATEMENTS OF INCOME (LOSS) - USD ($) shares in Thousands, $ in Thousands | 12 Months Ended | ||
|---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
| Revenues: | |||
| Total revenues | $ 3,659,374 | $ 3,094,238 | $ 2,363,567 |
| Operating expenses: | |||
| Cost of product sales (excluding amortization of acquired developed technologies) | 540,517 | 440,760 | 148,917 |
| Selling, general and administrative | 1,416,967 | 1,451,683 | 854,233 |
| Research and development | 590,453 | 505,748 | 335,375 |
| Intangible asset amortization | 599,169 | 525,769 | 259,580 |
| Impairment charge | 133,648 | 0 | 136,139 |
| Acquired in-process research and development | 444,148 | 0 | 251,250 |
| Total operating expenses | 3,724,902 | 2,923,960 | 1,985,494 |
| Income (loss) from operations | (65,528) | 170,278 | 378,073 |
| Interest expense, net | (288,242) | (278,766) | (99,707) |
| Foreign exchange loss | (19,014) | (4,350) | (3,271) |
| Income (loss) before income tax expense (benefit) and equity in loss of investees | (372,784) | (112,838) | 275,095 |
| Income tax expense (benefit) | (158,645) | 216,116 | 33,517 |
| Equity in loss of investees | 9,921 | 714 | 2,962 |
| Net income (loss) | $ (224,060) | $ (329,668) | $ 238,616 |
| Net income (loss) per ordinary share: | |||
| Basic (in dollars per share) | $ (3.58) | $ (5.52) | $ 4.28 |
| Diluted (in dollars per share) | $ (3.58) | $ (5.52) | $ 4.22 |
| Weighted-average ordinary shares used in per share calculations - basic (in shares) | 62,539 | 59,694 | 55,712 |
| Weighted-average ordinary shares used in per share calculations - diluted (in shares) | 62,539 | 59,694 | 56,517 |
| Product sales, net | |||
| Revenues: | |||
| Total revenues | $ 3,641,429 | $ 3,079,001 | $ 2,346,660 |
| Royalties and contract revenues | |||
| Revenues: | |||
| Total revenues | $ 17,945 | $ 15,237 | $ 16,907 |
JAZZ Balance Sheet
2022-12-31CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Dec. 31, 2022 | Dec. 31, 2021 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 881,482 | $ 591,448 |
| Accounts receivable, net of allowances of $17,843 and $13,813 at December 31, 2022 and 2021, respectively | 651,493 | 563,360 |
| Inventories | 714,061 | 1,072,721 |
| Prepaid expenses | 91,912 | 131,413 |
| Other current assets | 267,192 | 252,392 |
| Total current assets | 2,606,140 | 2,611,334 |
| Property, plant and equipment, net | 228,050 | 256,837 |
| Operating lease assets | 73,326 | 86,586 |
| Intangible assets, net | 5,794,437 | 7,152,328 |
| Goodwill | 1,692,662 | 1,827,609 |
| Deferred tax assets, net | 376,247 | 311,103 |
| Deferred financing costs | 9,254 | 12,029 |
| Other non-current assets | 55,139 | 40,813 |
| Total assets | 10,835,255 | 12,298,639 |
| Current liabilities: | ||
| Accounts payable | 90,758 | 100,298 |
| Accrued liabilities | 803,255 | 666,304 |
| Current portion of long-term debt | 31,000 | 31,000 |
| Income taxes payable | 7,717 | 9,608 |
| Deferred revenue | 463 | 2,093 |
| Total current liabilities | 933,193 | 809,303 |
| Deferred revenue, non-current | 0 | 463 |
| Long-term debt, less current portion | 5,693,341 | 6,018,943 |
| Operating lease liabilities, less current portion | 71,838 | 87,200 |
| Deferred tax liabilities, net | 944,337 | 1,300,541 |
| Other non-current liabilities | 106,812 | 116,998 |
| Commitments and contingencies (Note 14) | ||
| Shareholders’ equity: | ||
| Ordinary shares, nominal value $0.0001 per share; 300,000 shares authorized; 63,214 and 61,633 shares issued and outstanding at December 31, 2022 and 2021, respectively | 6 | 6 |
| Non-voting euro deferred shares, €0.01 par value per share; 4,000 shares authorized, issued and outstanding at both December 31, 2022 and 2021 | 55 | 55 |
| Capital redemption reserve | 472 | 472 |
| Additional paid-in capital | 3,477,124 | 3,534,792 |
| Accumulated other comprehensive loss | (1,125,509) | (400,360) |
| Retained earnings | 733,586 | 830,226 |
| Total shareholders’ equity | 3,085,734 | 3,965,191 |
| Total liabilities and shareholders’ equity | $ 10,835,255 | $ 12,298,639 |